These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29650801)

  • 1. The role of JAK2 inhibitors in MPNs 7 years after approval.
    Passamonti F; Maffioli M
    Blood; 2018 May; 131(22):2426-2435. PubMed ID: 29650801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
    Loscocco GG; Vannucchi AM
    Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutics in myeloproliferative neoplasms.
    Venugopal S; Mascarenhas J
    J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of JAK2 inhibitors.
    Verstovsek S
    Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes R; Mesa RA
    Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
    Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
    Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.